RXi Pharmaceuticals Corporation
257 Simarano Drive, Suite 101
Marlborough, MA 01752
(508) 767-3861
September 28, 2018
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attn: Dorrie Yale
| Re: | RXi Pharmaceuticals Corporation |
Registration Statement on Form S-1
Filed August 31, 2018
File No. 333-227173
Ladies and Gentlemen:
Pursuant to Rules 460 and 461 promulgated under the Securities Act of 1933, as amended, RXi Pharmaceuticals Corporation, a Delaware corporation (the “Company”), hereby respectfully requests that the effective time of the above referenced Registration Statement on Form S-1 filed by the Company (the “Registration Statement”) be accelerated to 5:00 p.m., Eastern Daylight Time, on, September 28, 2018 or as soon thereafter as practicable.
Very truly yours,
RXi Pharmaceuticals Corporation
/s/ Geert Cauwenbergh
Geert Cauwenbergh
President, Chief Executive Officer and acting Chief Financial Officer
cc: Ryan A. Murr, Gibson, Dunn & Crutcher LLP
